Table 3.
Results of the Cost-Effectiveness Analysis
LY | QALY | Costs | Difference, Apixaban vs Comparator | ICER (€/QALY) | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Total | Monitoring | Event | Drug | Cost | LY | QALY | ||||
Apixaban | 8.37 | 6.09 | 18,342 | 1068 | 13,356 | 3918 | ||||
Rivaroxaban | 8.32 | 6.05 | 18,385 | 1057 | 13,703 | 3625 | −43 | 0.05 | 0.03 | Apixaban dominates |
Dabigatran | 8.23 | 5.98 | 18,746 | 1046 | 14,588 | 3112 | −404 | 0.13 | 0.11 | Apixaban dominates |
Warfarin | 8.22 | 5.94 | 22,033 | 5877 | 16,008 | 149 | −3691 | 0.15 | 0.14 | Apixaban dominates |